[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
| Publication Type | Review |
| Authors | Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, Cigler T, Balogun O, Magge R, Liechty B, Karakatsanis N, Nehmeh S, Agee M, Jean J, Osborne J, Beal K, Schwartz T, Pannullo S, Knisely J, Ramakrishna R |
| Journal | Eur J Radiol |
| Volume | 181 |
| Pagination | 111791 |
| Date Published | 10/15/2024 |
| ISSN | 1872-7727 |
| Keywords | Brain Neoplasms, Breast Neoplasms, Estradiol, Positron-Emission Tomography, Radiopharmaceuticals, Receptors, Estrogen |
| Abstract | OBJECTIVE: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI. MATERIALS & METHODS: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected. Dedicated brain FES PET/CT or PET/MRI was performed for clinical purposes. Maximum standardized uptake value (SUV) in MRI-defined target lesions and SUV ratio (SUVR, referencing normal-appearing parenchyma) were obtained. Pathology and/or clinical and MRI follow-up data were used as gold standard to classify viable neoplasm versus post-radiotherapy (RT) sequelae. Mann-Whitney tests were performed to compare subgroups. RESULTS: Seven patients met inclusion criteria. 15/16 (94 %) lesions classified as neoplasm were FES-positive. 4/4 (100 %) lesions classified as RT sequelae were FES-negative. Median tumor FES-SUVR were higher than median RT-sequelae FES-SUVR (6.0 (2.8-9.1) versus 0.5 (0.3-0.7), p < 0.01), and similarly, median tumor FES-SUV were higher than median RT-sequelae FES-SUV (4.8 (2.8-9.1) versus 0.6 (0.3-0.8), p < 0.01). Lesion-based analysis of FDG-SUV and -SUVR demonstrated a trend for higher FDG avidity in lesions characterized as neoplasm; however, this did not reach statistical significance. CONCLUSION: Dedicated FES brain PET represents a promising adjunct modality, noting limitations of small sample size, retrospective nature of our study, and the possibility of ER expression heterogeneity. Our findings merit future prospective clinical trials incorporating dedicated brain FES PET/CT and PET/MRI in the management of patients with ER-positive disease and BCBM. |
| DOI | 10.1016/j.ejrad.2024.111791 |
| PubMed ID | 39423781 |